Biology of the lymphatic marker LYVE-1 and applications in research into lymphatic trafficking and lymphangiogenesis

APMIS

Volumn 112, Issue 7-8, 2004, Pages 526-538

  Jackson, David G ^a,b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

HA; Leukocyte trafficking; Lymphangiogenesis; LYVE 1; Tumour metastasis

Indexed keywords

BINDING PROTEIN; CD34 ANTIGEN; COMPLEMENTARY DNA; GLYCOSAMINOGLYCAN; HERMES ANTIGEN; HYALURONIC ACID; LINK PROTEIN; MEMBRANE RECEPTOR; MOLECULAR MARKER; PROTEIN LYVE 1; UNCLASSIFIED DRUG; VASCULOTROPIN C; VASCULOTROPIN D; VON WILLEBRAND FACTOR;

AMINO ACID SEQUENCE; ANGIOGENESIS; BREAST CARCINOMA; EXTRACELLULAR MATRIX; HEAD AND NECK CARCINOMA; HUMAN; LEUKOCYTE MIGRATION; LIGAND BINDING; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; MELANOMA; METASTASIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PANCREAS CARCINOMA; PRIORITY JOURNAL; REVIEW; THYROID CARCINOMA; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD44; BIOLOGICAL MARKERS; CELL MOVEMENT; GLYCOPROTEINS; HUMANS; HYALURONIC ACID; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; MOLECULAR SEQUENCE DATA; NEOPLASM METASTASIS;

EID: 10344222658     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2004.apm11207-0811.x     Document Type: Review

References (65)

1. Ryan TJ. Structure and function of lymphatics. J Invest Dermatol (Suppl) 1989;93:18S-24S.
2. Skobe M, Detmar M. Structure, function, and molecular control of the skin lymphatic system. J. Invest. Dermatol Symp Proc 2000;5:14-9.
3. von Andrian UH, Mempel TR. Homing and cellular traffic in lymph nodes. Nat Rev Immunol 2003;3:867-8.
4. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002;2:573-83.
5. Jackson DG, Prevo R, Clasper S, Banerji S. LYVE-1, the lymphatics and tumor lymphangiogenesis. Trends Immunol 2001;22:317-21.
6. Lee JY, Spicer AP. Hyaluronan: a multifunctional, megaDalton, stealth molecule. Curr Opin Cell Biol 2000;12:581-6.
7. Laurent TC, Fraser JR. Hyaluronan. FASEB J 1992;6:2397-404.
8. Weigel JA, Raymond RC, McGary CT, Singh A, Weigel PH. A blocking antibody to the hyaluronan (HA) receptor for endocytosis (HARE) inhibits HA clearance by perfused liver. J Biol Chem 2003;278:9808-12.
9. Jackson DG. Hyaluronan and lymphoedema. Lymphology 2004;37:1-5.
10. Noble PW. Hyaluronan and its catabolic products in tissue injury and repair. Matrix Biology 2002;21:25-9.
11. West DC, Kumar S. Hyaluronan and angiogenesis. Ciba Found Symp 1989;143:187-201.
12. Knudson CB, Knudson W. Hyaluronan-binding proteins in development, tissue homeostasis and disease. FASEB J 1993;7:1233-41.
13. Nandi A, Estess P, Siegelman MH. Hyaluronan anchoring and regulation on the surface of vascular endothelial cells is mediated through the functionally active form of CD44. J Biol Chem 2000;275:14939-48.
14. De Grendele HC, Estess P, Siegelman MH. Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science 1997;278:672-5.
15. Mohamadzadeh M, DeGrendele H, Arizpe H, Estess P, Siegelman M. Proinflammatory stimuli regulate endothelial hyaluronan expression and CD44/HA-dependent primary adhesion. J Clin Invest 1998;101:97-108.
16. Banerji S, Ni J, Wang SX, Clasper S, Su J, Tammi R, Jones M, Jackson DG. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 1999;144:789-801.
17. Prevo R, Banerji S, Ferguson D, Jackson DG. Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium. J Biol Chem 2001;276:19420-30.
18. Kohda D, Morton CJ, Parkar AA, Hatanaka H, Inagaki FM, Campbell ID, Day AJ. Solution structure of the link module: a hyaluronan binding domain involved in extracellular matrix stability and cell migration. Cell 1996;86:767-75.
19. Day AJ. Understanding hyaluronan-protein interactions. Glycoforum http://www.glycoforum.gr.jp/science/hyaluronan/HA16/HA16E.html. 2001.
20. Jackson DG. The lymphatics revisited: new perspectives from the hyaluronan receptor LYVE-1. Trends Cardiovasc Med 2003;13:1-7.
21. Skelton T, Zheng C, Nocks A, Stamenkovic I. Glycosylation provides both stimulatory and inhibitory effects on cell surface and soluble CD44 binding to hyaluronan. J Cell Biol 1998;140:431-46.
22. Wigle JT, Oliver G. Prox-1 function is required for the development of the murine lymphatic system. Cell 1999;98:769-78.
23. Wigle JT, Harvey N, Detmar M, Lagutina I, Grosveld G, Gunn MD, Jackson DG, Oliver G. An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J 2002;21:1505-13.
24. Jackson DG. New markers for the study of lymphangiogenesis. Anticancer Res 2001;7:1-5.
25. Tammi R, Rilla K, Pienimaki JP, MacCallum DK, Hogg M, Luukkonen M, Hascall VC, Tammi M. Hyaluronan enters keratinocytes by a novel endocytic route for catabolism. J Biol Chem 2001;276:35111-22.
26. Mandriota S, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, Banerji S, Huarte J, Montesano R, Jackson D, Orci L, Alitalo K, Christofori G, Pepper MS. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 2001;20:672-82.
27. Sabaratnam S, Levick JR. Molecular sieving of hyaluronan by synovial interstitial matrix and lymphatic capillary endothelium evaluated by lymph analysis in rabbits. Microvasc Res 2003;66:227-36.
28. Gee K, Kozlowski M, Kumar A. TNFα induces functionally active hyaluronan-adhesive CD44 by activating silidase through p38 mitogen-activated protein kinase in lipopolysaccharide-stimulated human monocytic cells. J Biol Chem 2003;278:37275-87.
29. Levesque MC, Haynes BF. TNFa and IL-4 regulation of hyaluronan binding to monocyte CD44 involves posttranslational modification of CD44. Cell Immunol 1999;193:209-18.
30. Lesley J, English N, Perschl A, Gregoroff J, Hyman R. Variant cell lines selected for alterations in the function of the hyaluronan receptor CD44 show differences in glycosylation. J Exp Med 1995;182:431-7.
31. English NM, Lesley JF, Hyman R. Site-specific de-N-glycosylation of CD44 can activate hyaluronan binding, and CD44 activation states show distinct threshold densities for hyaluronan binding. Cancer Res 1998;58:3736-42.
32. Katoh S, Zheng Z, Oritani K, Shimozato T, Kincade P. Glycosylation of CD44 negatively regulates its recognition of hyaluronan. J Exp Med 1996;182:419-29.
33. Liao H-X, Levesque MC, Patton K, Bergamo B, Jones D, Moody MA, Telen M, Haynes BF. Regulation of human CD44H and CD44E isoform binding to hyaluronan by phorbol myristate acetate and anti-CD44 monoclonal and polyclonal antibodies. J Immunol 1993;151:6490-9.
34. Katoh S, Miyagi T, Taniguchi H, Matsubara Y, Kadota J, Tominaga A, Kincade PW, Matsukura S, Kohno S. An inducible sialidase regulates the hyaluronic acid binding ability of CD44-bearing human monocytes. J Immunol 1999;162:5058-61.
35. Teriete P, Banerji S, Noble M, Blundell CD, Wright AJ, Pickford AR, Lowe E, Mahoney DJ, Tammi MI, Kahmann JD, Campbell ID, Day AJ, Jackson DG. Structure of the regulatory hyaluronan-binding domain in the inflammatory leukocyte homing receptor CD44. Mol Cell 2004;13:483-96.
36. Sabin FR. The lymphatic system in human embryos, with consideration of the morphology of the system as a whole. Am J Pathol 1902;1:367-89.
37. Salven P, Mustjoki S, Alitalo R, Alitalo K, Rafii S. VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood 2002;101:168-72.
38. He Y, Rajantie I, Ilmonen M, Makinen T, Karkkainen MJ, Haiko P, Salven P, Alitalo K. Pre-existing lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis. Cancer Res 2004;64:3737-40.
39. Abtahian F, Guerriero A, Lu MM, Zhou R, Mocsai A, Myers EE, Huang B, Jackson DG, Ferrari VA, Tybulewicz V, Lowell CA, Lepore JJ, Koretzky GA, Kahn ML. Separation of blood and lymphatic networks is regulated by the hematopoietic signaling proteins SLP-76 and SYK. Science 2002;299:247-51.
40. Cursiefen C, Schlotzer-Schrehardt U, Kuchle M, Sorokin L, Breiteneder-Geleff S, Alitalo K, Jackson DG. Lymphatic vessels in vascularized human corneas: immunohistochemical evidence using LYVE-1 and podoplanin. Invest Ophthalmol Vis Sci 2002;43:2127-35.
41. Cursiefen C, Chen L, Borges LP, Jackson DG, Cao J, Radziejewski C, D'Amore PA, Dana MR, Wiegand SJ, Streilin JW. VEGF-A stimulates lymphangiogenesis and haemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004;113:1040-50.
42. Schoppman SF, Birner P, Stockl J, Kalt R, Ullrich R, Caucig C, Kriehuber E, Nagy K, Alitalo K, Kerjaschki D. Tumor-associated macrophages express lymphatic enothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002;161:947-56.
43. Skobe M, Hawighorst T, Jackson DG, Janes L, Velasco P, Riccardi L, Claffey K, Detmar M. Induction of tumor lymphangiogenesis by vascular endothelial growth factor-C promotes breast cancer metastasis. Nature Med 2001;7:192-8.
44. Pepper MS. Lymphangiogenesis and tumor metastasis: myth or reality? Clin Cancer Res 2001;7:462-8.
45. Clarijs R, Ruiter DJ, de Waal RM. Lymphangiogenesis in malignant tumours: Does it occur? J Pathol 2001;193:143-6.
46. Jain RK, Fenton BT. Intratumoral lymphatic vessels: a case of mistaken identity or malfunction? J. Natl. Cancer Inst 2002;94:417-21.
47. Mattila MT, Ruohola JK, Karpanen T, Jackson DG, Selander KS, Alitalo K, Harkonen PL. VEGF-C induced lymphangiogenesis and lymph node metastasis in orthotopic MCF-7 tumors. Int J Cancer 2002;98:946-51.
48. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
49. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG. Vascular endothelial growth factor-D promotes tumour growth and spread via the lymphatics. Nature Med 2001;7:186-91.
50. Beasley NJP, Prevo R, Banerji S, Leek R, Moore J, van Trappen P, Cox G, Harris AL, Jackson DG. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res 2002;62:1315-20.
51. Maula SM, Luukkaa M, Grenman R, Jackson D, Jalkanen S, Ristamaki R. Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res 2003;63:1920-6.
52. Shields JD, Borsetti M, Rigby H, Harper SJ, Mortimer PS, Levick JR, Orlando A, Bates DO. Lymphatic density and metastatic spread in human malignant melanoma. Br J Cancer 2004;90:693-700.
53. Straume O, Jackson DG, Akslen LA. Independent prognostic impact of lymphatic vessel density and presence of low grade lymphangiogenesis in cutaneous melanoma. Clin Cancer Res 2003;9:150-5.
54. Dadras S, Paul T, Bertoncini J, Brown LF, Muzikansky A, Jackson DG, Ellwanger U, Garbe C, Mihm MC, Detmar M. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 2003;162:1951-60.
55. Hall FT, Freeman JL, Asa SL, Jackson DG, Beasley NJ. Intratumoral lymphatics and lymph node metastases in papillary thyroid carcinoma. Acta Otolaryngol Head Neck Surg 2003;129:716-9.
56. Von Marschall Z, Scholz A, Stacker S, Achen M, Jackson DG, Alves F, Schirner M, Haberey M, Thierauch KH, Wiedenmann B, Rosewicz S. Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in human pancreatic cancer. In Press 2004.
57. Leu AJ, Berk DA, Lymboussaki A, Alitalo K, Jain RK. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res 2000;60:4324-37.
58. Padera TP, Kadambi A, Di Tomaso E, Carreira CM, Brown EB, Boucher Y, Choi NC, Mathisen D, Wain J, Mark EJ, Munn LL, Jain RK. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002;296:1883-6.
59. Williams CSM, Leek RD, Robson AM, Banerji S, Prevo R, Harris AL, Jackson DG. Absence of intratumoral lymph vessels and lymphangiogenesis in human breast cancer. J Pathol 2003;200:195-206.
60. Bono P, Wasenius V, Lundin J, Jackson DG, Joensuu H. High peritumoral LYVE-1 positive lymphatic vessel numbers are associated with axillary lymph node metastases and poor outcome in early breast cancer. Clin Cancer Res 2004; (In Press).
61. Van Trappen PO, Steele D, Lowe DG, Baithun S, Beasley N, Thiele W, Weich H, Krishnan J, Shepherd JH, Pepper MS, Jackson DG, Sleeman JP, Jacobs IJ. Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3 during different stages of cervical carcinogenesis. J Pathol 2003;201:544-54.
62. Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, McClain J, Martin C, Witte C, Witte MH, Jackson DG, Sato T, Suri C, Campochiaro PA, Wiegand SJ, Yancopoulos GD. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev Cell 2002;3:411-23.
63. Yuan L, Moyon D, Pardanaud L, Breant C, Karkkainen MJ, Alitalo K, Eichmann A. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 2002;129:4797-806.
64. Peach RJ, Hollenbaugh D, Stamenkovic I, Aruffo A. Identification of hyaluronic acid binding sites in the extracellular domain of CD44. J Cell Biol 1993;122:257-64.
65. Bajorath J, Greenfield B, Munro SB, Day AJ, Aruffo A. Identification of CD44 residues important for hyaluronan binding and delineation of the binding site. J Biol Chem 1998;273:338-43.